Veeva Systems Inc.

NYSE:VEEV Stok Raporu

Piyasa değeri: US$30.6b

Veeva Systems Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Veeva Systems kazanç ve gelirin sırasıyla yıllık 12.7% ve 11% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 12.7% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 16.8% olacağı tahmin edilmektedir.

Anahtar bilgiler

12.7%

Kazanç büyüme oranı

12.74%

EPS büyüme oranı

Healthcare Services kazanç büyümesi22.1%
Gelir büyüme oranı11.0%
Gelecekteki özkaynak getirisi16.80%
Analist kapsamı

Good

Son güncelleme01 Jul 2026

Gelecekteki son büyüme güncellemeleri

Recent updates

Yeni Anlatı • Jul 03

AI-Powered Veeva Systems Poised for Solid Growth Amid Regulatory Stability

Investors often look for artificial intelligence winners in the obvious places: semiconductors, hyperscalers, and general-purpose software platforms. But some of the most durable AI opportunities may sit in far less glamorous places—inside the regulated workflows where a mistake is not merely inconvenient, but potentially delays a drug trial, a regulatory submission, or a therapy reaching patients.
Anlatı Güncellemesi • Jun 29

VEEV: AI Execution And CRM Wins Will Drive Future Upside

Veeva Systems’ analyst fair value estimate has been reset lower from about $380 to roughly $338, reflecting Street price target cuts as analysts weigh solid Q1 execution against AI disruption risk, competitive CRM questions, and a shift toward more measured profit margin and P/E assumptions. Analyst Commentary Street research on Veeva Systems presents a mixed but generally constructive picture, with many firms recalibrating price targets while still pointing to solid Q1 execution, ongoing demand in health technology, and emerging AI and CRM catalysts as key elements in their valuation work.
Seeking Alpha • Jun 24

Veeva Systems: The AI Thesis Is More Tangible Now

Summary Veeva Systems remains a Buy, with core revenue and subscription growth in the mid-teens and a compelling ~16x NTM PE valuation. Falcon, VEEV's agentic labor AI platform, makes the AI opportunity tangible, offering automation for compliance-sensitive, high-volume workflows in life sciences. R&D and Quality subscription revenue outpaces consolidated growth at 19% y/y, while Commercial gains traction with over 150 live Vault CRM customers. VEEV's valuation does not require immediate AI monetization; continued core business compounding and successful CRM migrations underpin upside potential. Read the full article on Seeking Alpha
Analiz Makalesi • Jun 20

Veeva Systems (VEEV) Stock Could Be 38% Undervalued After Fed Driven Pullback

Veeva Systems (VEEV) shares fell after the Federal Reserve held its benchmark rate and signaled a more restrictive stance, as higher Treasury yields weighed on software sector valuations, including healthcare and life sciences platforms. See our latest analysis for Veeva Systems. At around US$153.30, Veeva Systems’ recent share price weakness has been broad based, with a 1 day share price return of 1% and a year to date share price return down 30.16%, while the 1 year total shareholder return...
Anlatı Güncellemesi • Jun 15

VEEV: AI Execution And CRM Wins Will Support Future Multiple Reacceleration

Narrative Update The analyst price target for Veeva Systems in this framework is updated from about $263 to about $245, as analysts balance solid Q1 execution and raised guidance with AI disruption risk, CRM competition from Salesforce, and questions around the quality and mix of recent upside, particularly in services. Analyst Commentary Recent research on Veeva Systems reflects a split view, with most analysts acknowledging solid Q1 execution and raised guidance, but debating how much weight to give AI disruption risk, CRM competition, and the quality of services driven upside when thinking about valuation, execution, and long term growth.
Anlatı Güncellemesi • Jun 01

VEEV: AI Moat And CRM Commitments Will Support Future Multiple Reacceleration

Narrative Update The analyst price target for Veeva Systems has been trimmed by about $2 to $262.68 as analysts factor in compressed software multiples, while largely maintaining their underlying growth, margin, and P/E assumptions. Analyst Commentary Recent research on Veeva Systems clusters around strong reported execution in Q4, tempered by valuation resets tied to compressed software multiples and longer term questions around AI and CRM competition.
Anlatı Güncellemesi • May 11

VEEV: AI Moat And CRM Commitments Will Support Premium Multiple

Veeva Systems' updated analyst price target edges lower to about $264 from roughly $265, as analysts keep their broadly positive take on the company's recent Q4 results but adjust valuation assumptions to reflect compressed software multiples and ongoing debates around AI, R&D growth, and CRM stability. Analyst Commentary Recent research on Veeva reflects a mix of optimism about execution in Q4 and caution around valuation and longer term growth drivers.
Anlatı Güncellemesi • Apr 25

VEEV: AI Moat And Subscription Resilience Will Support Premium Multiple

Analysts have trimmed the Veeva Systems price target slightly, with the model fair value moving from about $270.93 to $264.46, as modestly lower assumed future P/E multiples more than offset largely unchanged growth and margin expectations. Analyst Commentary Recent Street research around Veeva Systems shows a split view, with many firms trimming price targets while still pointing to solid execution and specific areas of uncertainty that could influence the valuation over time.
Anlatı Güncellemesi • Apr 08

VEEV: AI And Subscription Resilience Will Support Premium Software Multiple

Analysts trimmed the blended Veeva Systems price target by aligning with sector wide software multiple compression, even as they point to strong Q4 execution, resilient subscription growth, and an emerging AI and product pipeline as key longer term supports. Analyst Commentary Recent Street research around Veeva Systems reflects a mix of optimism on execution and growth, alongside more cautious views on competitive risk, AI impact, and valuation.
Anlatı Güncellemesi • Mar 25

VEEV: AI Adoption In R&D Workflows Will Support Durable Premium Outlook

Analysts have adjusted their price targets on Veeva Systems into a roughly $190 to $317 range, generally trimming prior targets by tens of dollars as software valuation multiples compress, even after what they describe as solid Q4 results and broadly constructive longer term fundamentals. Analyst Commentary Recent research paints a mixed but generally constructive picture for Veeva Systems, with most firms trimming price targets while still pointing to solid execution and durable fundamentals.
Anlatı Güncellemesi • Mar 11

VEEV: AI Adoption And CRM Commitments Will Support Durable Premium Outlook

We are trimming our Veeva Systems fair value estimate to $270.93 from $302.60, as analysts broadly reset price targets in response to sector wide software multiple compression and slightly more measured assumptions for revenue growth, margins, and future P/E multiples, despite generally solid Q4 results and guidance. Analyst Commentary Street research on Veeva Systems has become more mixed, with many firms cutting price targets while still acknowledging solid Q4 execution and robust profitability.
Anlatı Güncellemesi • Feb 25

VEEV: AI Execution And CRM Stability Will Support Durable Premium Outlook

Our fair value estimate for Veeva Systems has edged down from $308.63 to $302.60. This reflects a series of reduced Street price targets as analysts weigh maturing products, competitive pressures, software sentiment, and the balance of growth opportunities against current valuation.
Anlatı Güncellemesi • Feb 10

VEEV: Roche Commitment And CRM Retention Will Support Durable Premium Outlook

Our analyst fair value estimate for Veeva Systems has been trimmed slightly to $308.63. This reflects a modest reset in Street price targets as analysts balance concerns about slower growth in maturing products and competitive pressure with ongoing strengths in areas like Crossix, AI adoption, and large CRM wins such as Roche.
Yeni Anlatı • Jan 28

Rising Life Sciences Cloud Standardization And AI Adoption Will Support Strong Long Term Upside

Catalysts About Veeva Systems Veeva Systems provides cloud based software, data and consulting services to life sciences companies across commercial, R&D and manufacturing functions. What are the underlying business or industry changes driving this perspective?
Anlatı Güncellemesi • Jan 27

VEEV: Roche Rollout And CRM Retention Will Support Durable Premium Outlook

The analyst price target embedded in our Veeva Systems model edges slightly lower to about US$310 from roughly US$311. This reflects a blend of more cautious views on growth and competitive pressure, along with offsetting positive views on durable margins, CRM customer retention, and newer areas such as Crossix and early AI traction.
Anlatı Güncellemesi • Jan 12

VEEV: Roche Expansion And CRM Migrations Will Support Durable Premium Outlook

Analysts have trimmed their fair value estimate for Veeva Systems by about US$1 to US$310.98, reflecting modest adjustments to discount rate and growth assumptions while still pointing to what they see as durable growth drivers such as pharma CRM migrations, broader Vault adoption and newer areas like Crossix and AI. Analyst Commentary Recent Street research on Veeva Systems reflects a mix of optimism and caution, with differing views clustering around the durability of growth in CRM and Vault, the timing of pharma migrations, and how current valuation stacks up against execution and contract wins.
Anlatı Güncellemesi • Dec 19

VEEV: Roche Commitment And CRM Migrations Will Likely Sustain Premium Outlook

Analysts have modestly trimmed their blended price target for Veeva Systems to about $312 from roughly $321, reflecting a slightly higher discount rate and lower implied future multiple, even as they highlight accelerating CRM migrations, including Roche's global Vault CRM rollout, and improving long term growth and margin expectations. Analyst Commentary Street research remains broadly constructive on Veeva Systems, with recent target changes reflecting a recalibration of software multiples rather than a material shift in company specific fundamentals.
Analiz Makalesi • Dec 03

Veeva Systems' (NYSE:VEEV) Performance Is Even Better Than Its Earnings Suggest

Investors were underwhelmed by the solid earnings posted by Veeva Systems Inc. ( NYSE:VEEV ) recently. We have done...
Anlatı Güncellemesi • Nov 11

VEEV: Continued Momentum And New Commitments Will Likely Sustain Premium Outlook

Analysts have significantly raised their price targets on Veeva Systems, with recent updates moving targets as high as $380. They cite the company's strong sales growth prospects and solid momentum, driven by accelerating CRM customer commitments and new partnerships.
Anlatı Güncellemesi • Oct 27

Pharma Wins And New Partnerships Will Drive Cloud Momentum In Coming Quarters

Veeva Systems' analyst price target saw a significant increase, rising by more than $80 to reflect higher expectations for sales growth and ongoing customer commitments. Analysts cited the company’s strengthening position in CRM and positive momentum across key pharma relationships.
Anlatı Güncellemesi • Oct 13

IQVIA Resolution And Embedded AI Will Expand Digital Healthcare Cloud

Narrative Update on Veeva Systems: Analyst Price Target Revision Analysts have raised their fair value estimate for Veeva Systems to approximately $321 per share, up by nearly $4. They cited stronger than expected sales momentum, driven by new major customer commitments and continued growth in key business segments.
Anlatı Güncellemesi • Aug 29

Data Cloud Expansion And AI Efficiencies Will Drive Future Success

Analysts have raised their price target for Veeva Systems to $314.71, citing strong Q2 “beat and raise” results, momentum in both Commercial and R&D segments, successful Vault CRM rollouts with major pharma clients, and ongoing market share gains in life sciences CRM. Analyst Commentary Bullish analysts highlighted Veeva's strong “beat and raise” Q2 results, with both subscription and services revenues growing solidly year-over-year, driven by performance in both Commercial and R&D technology segments.
Analiz Makalesi • Jul 11

If EPS Growth Is Important To You, Veeva Systems (NYSE:VEEV) Presents An Opportunity

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Seeking Alpha • Apr 17

Veeva Systems: Substantially Overvalued As Growth Slows

Summary Veeva Systems is overvalued, trading at frothy levels despite only ~10% growth, and facing a potential slowdown in 2025; I recommend a sell rating. The company excels in the life sciences vertical with unique solutions but its ambitious revenue targets (doubling revenue by 2030) may be tough to achieve organically. Valuation multiples are high at ~10 EV/FY26 revenue and ~30x FY26 P/E, well above a number of peers - some of which are growing even faster than Veeva. Read the full article on Seeking Alpha
Seeking Alpha • Mar 19

Veeva Systems: Staying Buy Rated As VEEV Is Executing Well

Summary I reaffirm my buy rating on Veeva Systems due to strong 4Q25 results, driven by R&D growth and positive Vault CRM adoption traction. VEEV's revenue grew 14% y/y to $721 million, beating expectations, with significant margin improvements and a strong balance sheet. Vault CRM added 20 new customers, with multiple top 20 pharma commitments expected in 2025, signaling positive transition progress. Data Cloud segment shows strong momentum, with new initiatives like Pulse expected to drive further CRM adoption and growth. Read the full article on Seeking Alpha
Seeking Alpha • Mar 07

Veeva Systems: Solid Q4 With Margin Expansion

Summary I reiterate my “Strong Buy” rating on Veeva Systems Inc. with a one-year target price of $275 per share due to strong CRM migration and margin improvement. Veeva reported 14.3% revenue growth and 28.7% adjusted operating profit growth, driven by robust CRM adoption and billing growth. Management's guidance for FY26 includes $3.04-$3.055 billion in revenue, with anticipated 12% revenue growth despite high-interest rate challenges. I foresee continued margin expansion and revenue growth recovery to 16% by FY27 for VEEV, supported by CRM migration and easing capital funding challenges. Read the full article on Seeking Alpha
Seeking Alpha • Jan 28

Veeva Systems: Forget The Short-Term Volatility; The Long Term Is Promising

Summary I rate Veeva Systems as a 'Buy' due to its strong performance recovery, despite competition from Salesforce and industry uncertainties under Trump's administration. VEEV's migration to its own CRM, Veeva Vault, is a long-term tailwind, enhancing its ecosystem and competitive edge. The Company's Q3 2025 results exceeded expectations, with significant revenue, net income, and free cash flow growth, raising FY 2025 guidance. Despite short-term volatility, Veeva's specialization in life sciences, strong balance sheet, and innovative culture position it well for long-term growth. Read the full article on Seeking Alpha

Kazanç ve Gelir Büyüme Tahminleri

NYSE:VEEV - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
1/31/20294,5891,3851,9762,00417
1/31/20284,0801,1891,7441,79928
1/31/20273,6431,0601,5691,57728
4/30/20263,3199421,6401,665N/A
1/31/20263,1959091,3861,415N/A
10/31/20253,0808601,3511,378N/A
7/31/20252,9688101,3281,349N/A
4/30/20252,8557811,1861,204N/A
1/31/20252,7477141,0701,090N/A
10/31/20242,6566661,0551,078N/A
7/31/20242,574615972997N/A
4/30/20242,4885561,1371,169N/A
1/31/20242,364526885911N/A
10/31/20232,296567895917N/A
7/31/20232,232540955977N/A
4/30/20232,176519791805N/A
1/31/20232,155488767780N/A
10/31/20222,077396758771N/A
7/31/20222,001394731741N/A
4/30/20221,922412753767N/A
1/31/20221,851427750764N/A
10/31/20211,762433768779N/A
7/31/20211,663424750761N/A
4/30/20211,562409736747N/A
1/31/20211,465380543551N/A
10/31/20201,380343513522N/A
7/31/20201,283329482488N/A
4/30/20201,196314481483N/A
1/31/20201,104301N/A437N/A
10/31/20191,025306N/A430N/A
7/31/2019969288N/A410N/A
4/30/2019911259N/A397N/A
1/31/2019862230N/A311N/A
10/31/2018816199N/A280N/A
7/31/2018768170N/A271N/A
4/30/2018726158N/A242N/A
1/31/2018691151N/A233N/A
10/31/2017655132N/A230N/A
7/31/2017620119N/A223N/A
4/30/201758493N/A177N/A
1/31/201755178N/A144N/A
10/31/201650865N/A150N/A
7/31/201647254N/A144N/A
4/30/201643954N/A148N/A
1/31/201640954N/A80N/A
10/31/201538250N/A75N/A
7/31/201535950N/A90N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: VEEV 'nin tahmini kazanç büyümesi (yıllık 12.7% ) tasarruf oranının ( 3.5% ) üzerindedir.

Kazançlar ve Piyasa: VEEV şirketinin kazançlarının (yıllık 12.7% ) US pazarından (yıllık 18.2% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: VEEV şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: VEEV şirketinin gelirinin (yıllık 11% ) US pazarından (yıllık 12.9% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: VEEV şirketinin gelirinin (yıllık 11% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: VEEV 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 16.8 %).

Büyüyen şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/07/09 16:58
Gün Sonu Hisse Fiyatı2026/07/09 00:00
Kazançlar2026/04/30
Yıllık Kazançlar2026/01/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Veeva Systems Inc. 43 Bu analistlerden 28, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Joseph VruwinkBaird
Saket KaliaBarclays
Sean DodgeBMO Capital Markets Equity Research